5 Best Small-Cap Biotech Stocks Under $10 in 2021

4. Dynavax Technologies Corp. DVAX (NASDAQ: DVAX)

No of Hedge Funds: 23

Total Value of HF Holdings: $58 Million

Dynavax makes treatment for human body’s immune system stability. The company works on adjuvant vaccine for hepatitis B by utilizing expertise of Toll-like Receptor (TLR) biology. It is known for Hepatitis B vaccine HEPLISAV-B.

In January 2021, Dynavax Technologies Corporation announced that the first participant has been dosed in the Phase 2 clinical trial evaluating MVC’s COVID-19 vaccine candidate, MVC- COV1901. MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax.